Description
Product details
Respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) often require a dual-acting therapy that can provide both rapid symptom relief and long-term inflammation control. BUDESHINE F 200 is a scientifically advanced inhalation therapy that combines Formoterol Fumarate (a long-acting bronchodilator) and Budesonide (a corticosteroid). This dual formulation is designed to target the root causes of breathing difficulties—airway inflammation and bronchoconstriction—providing patients with improved lung function, reduced symptoms, and better quality of life. Composition Each dose of BUDESHINE F 200 contains: Formoterol Fumarate – A long-acting β2-adrenergic agonist (LABA) Budesonide 200 mcg – An inhaled corticosteroid (ICS) Mechanism of Action Formoterol Fumarate Acts as a long-acting bronchodilator. Stimulates β2-receptors in the airway smooth muscle, leading to relaxation and widening of bronchial passages. Provides rapid onset (within minutes) and sustained action for up to 12 hours, ensuring long-lasting relief from breathlessness and wheezing. Budesonide A potent corticosteroid with powerful anti-inflammatory properties. Reduces swelling, irritation, and mucus production in the airways. Helps prevent asthma attacks and COPD exacerbations when used regularly. Together, this combination ensures symptom relief, prevention of flare-ups, and long-term disease control. Therapeutic Indications BUDESHINE F 200 is prescribed for: Asthma – maintenance therapy for patients requiring both a bronchodilator and corticosteroid. Chronic Obstructive Pulmonary Disease (COPD) – including chronic bronchitis and emphysema. Prevention of Exercise-Induced Bronchospasm (when used as maintenance therapy).
